Matthew Hayward
Vice President - Drug Discovery Magnet Biomedicine
Seminars
Thursday 29th January 2026
Magnet Biomedicine’s Trueglue Platform: The Systematic Discovery of Molecular Glue Inhibitors for Therapeutic Intervention
3:00 pm
- Magnet Biomedicine is pioneering the discovery of novel molecular glue inhibitor (MGI) medicines through its unique platform to address areas of high unmet medical need, including oncology, immunology, and inflammation
- Rationally designed TrueGlues target previously intractable proteins of interest and localize therapeutic effects to disease-relevant tissues, offering unique opportunities to increase the therapeutic index by minimizing on-target, off-tissue toxicity
- The presentation will highlight the MagnetBio TrueGlue discovery platform and share data from our lead programs
